Back to top
more

TELESIS BIO (TBIO)

(Delayed Data from NSDQ)

$0.32 USD

0.32
26,223

0.00 (-0.93%)

Updated Apr 26, 2024 03:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sanofi (SNY) Q1 Earnings, Sales Grow on Coronavirus-Led Buying

by Zacks Equity Research

Sanofi (SNY) beats estimates for both earnings and sales. Around half of the sales and earnings growth at CER was due to COVID-19 associated patient stockpiling. Stock down.

Sanofi/Luminostics to Make Self-Testing Solution for Coronavirus

by Zacks Equity Research

Sanofi (SNY) partners with Luminostics to make a COVID-19 smartphone-based self-testing solution, which will be based on the latter's proprietary technology.

Moderna Rallies on US Government Grant for Coronavirus Vaccine

by Zacks Equity Research

Moderna (MRNA) gets a commitment of up to $483 million from the U.S. Government Agency BARDA to accelerate the development of its mRNA-based coronavirus vaccine.

Sanofi and Glaxo Collaborate to Develop Coronavirus Vaccine

by Zacks Equity Research

Sanofi (SNY) and Glaxo are contributing their proven technologies to develop a coronavirus vaccine, which may be manufactured at large scale.

Moderna Stock Surges 78% YTD on Coronavirus Vaccine Progress

by Zacks Equity Research

Moderna (MRNA) is making significant progress in development of coronavirus vaccine. It is actively preparing for a potential phase II study.

Ekta Bagri headshot

Coronavirus Vaccine Race Intensifies: 3 Stocks in Focus

by Ekta Bagri

Given the urgent need for preventing the spread of COVID-19 in future, let's take a look at the companies developing vaccines for the same.

Sweta Jaiswal, FRM headshot

Biotech Stocks & ETFs to Gain on Progress in COVID-19 Vaccine Development

by Sweta Jaiswal, FRM

The rampant race to introduce a vaccine for the COVID-19 is creating near-term opportunities, making the biotech sector a lucrative space for investments.

J&J Plans to Initiate Coronavirus Vaccine Study in September

by Zacks Equity Research

J&J (JNJ) announces its plan to start an early-stage clinical study on its selected vaccine candidate in September. The company also expands agreement with BARDA to accelerate vaccine development.

Translate Bio, Sanofi to Jointly Develop Coronavirus Vaccine

by Zacks Equity Research

Translate Bio (TBIO) gains on collaboration with Sanofi for a mRNA vaccine development for COVID-19.

Translate Bio (TBIO) Surges: Stock Moves 5.5% Higher

by Zacks Equity Research

Translate Bio (TBIO) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Translate Bio, Inc. (TBIO) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Translate Bio, Inc. (TBIO) delivered earnings and revenue surprises of -33.33% and 27.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Translate Bio, Inc. (TBIO) Q4 Earnings Expected to Decline

by Zacks Equity Research

Translate Bio, Inc. (TBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Translate Bio, Inc. (TBIO) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Translate Bio, Inc. (TBIO) delivered earnings and revenue surprises of 8.89% and -28.31%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Translate Bio, Inc. (TBIO) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Translate Bio, Inc. (TBIO) delivered earnings and revenue surprises of -26.67% and -32.26%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Nitish Marwah headshot

IPOs and Foreign Investment Propel Biotech: 4 Top Picks

by Nitish Marwah

A steady influx of foreign as well as domestic investments in U.S. biotech has gone a long way in boosting gains for the space.

    Benjamin Rains headshot

    IPOs Are Heating Up Once Again

    by Benjamin Rains

    A few big-name companies have grabbed the lion's share of the IPO limelight so far this year, including major tech players Spotify (SPOT) and Dropbox (DBX). Meanwhile, some investors might have missed just how busy 2018 has been, in fact, June could end up being the busiest month of initial public offerings in three years.